公开(公告)号：US20210355193A1

公开(公告)日：2021-11-18

申请号：US16641580

申请日：2018-08-23

申请人： KOREA (CENTER FOR DISEASE CONTROL AND PREVENTION) ,  NIH Office of Tech Transfer

发明人： Hansaem Lee ,  Janghoon Choi ,  Sungsoon Kim ,  Lingshu Wang ,  Barney Graham ,  John Mascola

IPC分类号： C07K16/10 ,  G01N33/569

摘要： The present invention relates to monoclonal antibodies for a spike protein of the Middle East respiratory syndrome coronavirus (MERS-CoV), and a use thereof. Particularly, monoclonal antibodies 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1 and 90-F2 according to the present invention have excellent attachment force with respect to a full-length spike protein of MERS-CoV and the Si domain of the protein, and, of the monoclonal antibodies, the monoclonal antibodies 90-F1, 90-E5, 90-E6, 90-F2, 77-A5 and 77-A6 have excellent attachment force with respect to an RBD antigen of MERS-CoV. Also, the antibodies 77-A5, 77-A6, 90-E5, 90-E6, 90-F1 and 90-F2 exhibit neutralizing capacity with respect to a MERS pseudovirus and MERS-CoV, and the antibodies 90-B2 and 90-B7 exhibit neutralizing capacity only with respect to MERS-CoV. Further, the monoclonal antibodies have a particular monomeric form, and have excellent stability and thus may be useful for treating or diagnosing MERS.

公开(公告)号：US12077572B2

公开(公告)日：2024-09-03

申请号：US17952308

申请日：2022-09-25

申请人： The United States of America, as represented by the Secretary, Department of Health and Human Services ,  Korea (Center for Disease Control and Prevention)

发明人： Hansaem Lee ,  Janghoon Choi ,  Sungsoon Kim ,  Lingshu Wang ,  Barney Graham ,  John R Mascola

IPC分类号： C07K16/10 ,  G01N33/569

CPC分类号： C07K16/10 ,  G01N33/56983 ,  C07K2317/565 ,  C07K2317/76 ,  G01N2333/165

摘要： The present invention relates to monoclonal antibodies for a spike protein of the Middle East respiratory syndrome coronavirus (MERS-CoV), and a use thereof. Particularly, monoclonal antibodies 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1 and 90-F2 according to the present invention have excellent attachment force with respect to a full-length spike protein of MERS-CoV and the S1 domain of the protein, and, of the monoclonal antibodies, the monoclonal antibodies 90-F1, 90-E5, 90-E6, 90-F2, 77-A5 and 77-A6 have excellent attachment force with respect to an RBD antigen of MERS-CoV. Also, the antibodies 77-A5, 77-A6, 90-E5, 90-E6, 90-F1 and 90-F2 exhibit neutralizing capacity with respect to a MERS pseudovirus and MERS-CoV, and the antibodies 90-B2 and 90-B7 exhibit neutralizing capacity only with respect to MERS-CoV. Further, the monoclonal antibodies have a particular monomeric form, and have excellent stability and thus may be useful for treating or diagnosing MERS.

公开(公告)号：US20230265169A1

公开(公告)日：2023-08-24

申请号：US17952308

申请日：2022-09-25

申请人： The United States of America, as represented by the Secretary, Department of Health & Human Services ,  Korea (Center for Disease Control and Prevention)

发明人： Hansaem Lee ,  Janghoon Choi ,  Sungsoon Kim ,  Lingshu Wang ,  Barney Graham ,  John R Mascola

IPC分类号： C07K16/10 ,  G01N33/569

CPC分类号： C07K16/10 ,  G01N33/56983 ,  C07K2317/565 ,  C07K2317/76 ,  G01N2333/165

摘要： The present invention relates to monoclonal antibodies for a spike protein of the Middle East respiratory syndrome coronavirus (MERS-CoV), and a use thereof. Particularly, monoclonal antibodies 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1 and 90-F2 according to the present invention have excellent attachment force with respect to a full-length spike protein of MERS-CoV and the S1 domain of the protein, and, of the monoclonal antibodies, the monoclonal antibodies 90-F1, 90-E5, 90-E6, 90-F2, 77-A5 and 77-A6 have excellent attachment force with respect to an RBD antigen of MERS-CoV. Also, the antibodies 77-A5, 77-A6, 90-E5, 90-E6, 90-F1 and 90-F2 exhibit neutralizing capacity with respect to a MERS pseudovirus and MERS-CoV, and the antibodies 90-B2 and 90-B7 exhibit neutralizing capacity only with respect to MERS-CoV. Further, the monoclonal antibodies have a particular monomeric form, and have excellent stability and thus may be useful for treating or diagnosing MERS.